Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

INTRODUCTION: Type 2 diabetes represents a continuing healthcare challenge, and choosing cost-effective treatments is crucial to ensure that healthcare resources are used efficiently. The present analysis assessed the cost-effectiveness of once-weekly semaglutide 1 mg versus empagliflozin 25 mg for...

Descripción completa

Detalles Bibliográficos
Autores principales: Capehorn, Matthew, Hallén, Nino, Baker-Knight, James, Glah, Divina, Hunt, Barnaby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846640/
https://www.ncbi.nlm.nih.gov/pubmed/33423240
http://dx.doi.org/10.1007/s13300-020-00989-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846640/
https://www.ncbi.nlm.nih.gov/pubmed/33423240
http://dx.doi.org/10.1007/s13300-020-00989-6

Ejemplares similares